MRNA Stock Chart & Stats
$2508.99
-$48.00(-4.82%)
At close: 4:00 PM EDT
$2508.99
-$48.00(-4.82%)
Day’s Range― - ―
52-Week Range$414.00 - $3,440.00
Previous CloseN/A
Volume179.00
Average Volume (3M)2.68K
Market Cap
$1.28T
Enterprise Value$24.02K
Total Cash (Recent Filing)$5.14B
Total Debt (Recent Filing)$1.29B
Price to Earnings (P/E)―
Beta1.06
Next Earnings
Oct 29, 2026EPS Estimate
-18.66Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-7.98
Shares Outstanding399,235,900
10 Day Avg. Volume1,684
30 Day Avg. Volume2,682
Financial Highlights & Ratios
PEG Ratio0.19
Price to Book (P/B)1.33
Price to Sales (P/S)5.90
P/FCF Ratio-5.56
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$1,903.05Price Target Upside-24.15% Downside
Rating ConsensusHold
Number of Analyst Covering20
EPS Forecast (FY)-146.07
Revenue Forecast (FY)$36.88B
Bulls Say, Bears Say
Bulls Say
Respiratory Portfolio ExpansionMultiple respiratory products are advancing through approvals and procurement, reducing reliance on a single marketed vaccine over time. Expanded geographic access and a positive regulatory recommendation create additional commercial opportunities across seasonal flu, RSV, and COVID-19 markets.
Improving Cost EfficiencyLower manufacturing, research, and commercial expenses show management is adapting the cost base to the post-pandemic revenue environment. Sustained efficiency gains can extend the company’s funding runway and improve the path toward restoring operating leverage as products mature.
Clinical Pipeline ProgressA broad pipeline spanning oncology and rare diseases provides potential growth options beyond COVID vaccines. Full enrollment and advancing registrational work indicate development execution and preserve long-term opportunities to build recurring product revenue from proprietary mRNA technology.
Bears Say
Persistent Losses And Cash BurnOngoing operating losses and negative free cash flow mean Moderna is not currently self-funding its research and commercial activities. Continued cash consumption can reduce financial flexibility over the next several quarters and makes profitability recovery dependent on revenue growth and further cost reductions.
COVID Revenue ExposureModerna remains materially exposed to changing COVID booster demand while newer products are not yet contributing to 2026 guidance. If vaccination rates continue to decline, weaker core product revenue could constrain investment capacity and increase pressure on the pipeline to replace lost sales.
Norovirus Development SetbackThe interim miss raises uncertainty around the timing and probability of a potential norovirus product, while additional enrollment extends development duration and expense. A delayed or unsuccessful program would remove one avenue for broadening the commercial portfolio beyond respiratory vaccines.
Moderna News
MRNA FAQ
What was Moderna’s price range in the past 12 months?
Moderna lowest stock price was $414.00 and its highest was $3440.00 in the past 12 months.
What is Moderna’s market cap?
Moderna’s market cap is $1.28T.
When is Moderna’s upcoming earnings report date?
Moderna’s upcoming earnings report date is Oct 29, 2026 which is in 34 days.
How were Moderna’s earnings last quarter?
Moderna released its earnings results on Jul 31, 2026. The company reported -$33.444 earnings per share for the quarter, beating the consensus estimate of -$34.496 by $1.053.
Is Moderna overvalued?
According to Wall Street analysts Moderna’s price is currently Overvalued.
Does Moderna pay dividends?
Moderna does not currently pay dividends.
What is Moderna’s EPS estimate?
Moderna’s EPS estimate is -18.66.
How many shares outstanding does Moderna have?
Moderna has 399,235,900 shares outstanding.
What happened to Moderna’s price movement after its last earnings report?
Moderna reported an EPS of -$33.444 in its last earnings report, beating expectations of -$34.496. Following the earnings report the stock price went down -3.411%.
Which hedge fund is a major shareholder of Moderna?
Currently, no hedge funds are holding shares in MX:MRNA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Moderna Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$1,903.05 (-24.15% Downside)
$1,903.05 (-24.15% Downside)
Blogger Sentiment
Neutral
MX:MRNA Sentiment 57%
Sector Average 64%
Sector Average 64%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
652.78%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-8.73%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Moderna
Moderna, Inc., a biotechnology firm, is dedicated to the discovery, development, and commercialization of messenger RNA (mRNA) based therapies and preventive medicines. Its extensive research and development efforts target a broad spectrum of medical needs, including infectious diseases, cancer immunology, rare conditions, cardiovascular ailments, and autoimmune disorders, with operations spanning the United States, Europe, and other global markets. The company's diverse product pipeline encompasses various vaccine candidates: those for respiratory illnesses like COVID-19, influenza, and respiratory syncytial virus (RSV); latent viral infections such as cytomegalovirus (CMV), Epstein-Barr virus (EBV), human immunodeficiency virus (HIV), herpes simplex virus (HSV), and varicella-zoster virus (VZV); and public health threats like Zika and Nipah. Additionally, Moderna is advancing systemic secreted and cell surface-targeted therapeutics, an array of cancer vaccines (including personalized, KRAS, and checkpoint varieties), intratumoral immuno-oncology products, localized regenerative treatments, systemic intracellular medicines, and inhaled pulmonary solutions. Moderna maintains strategic alliances with several prominent entities, including AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, Carisma Therapeutics, Inc., Metagenomi, Inc., the Defense Advanced Research Projects Agency (DARPA), the Biomedical Advanced Research and Development Authority (BARDA), the Institute for Life Changing Medicines, and The Bill & Melinda Gates Foundation. It also holds a collaboration and license agreement with Chiesi Farmaceutici S.P.A. Founded in 2010 as Moderna Therapeutics, Inc., the company officially became Moderna, Inc. in August 2018. Its corporate headquarters are located in Cambridge, Massachusetts.
MRNA Company Deck
MRNA Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed meaningful commercial and clinical progress — a Q2 revenue beat, multiple regulatory and market milestones (including a VRBPAC recommendation for the flu candidate and expanded approvals for respiratory products), clear cost and efficiency improvements, and advancing oncology/rare disease programs with important data and new dosing initiatives. These positives were tempered by a norovirus Phase III interim that did not meet early success criteria and slower case accrual, a significant litigation settlement payment (~$950M) that reduced cash, a substantial net loss and continued cash burn, and timing uncertainty for several event‑driven readouts. On balance, the highlights (regulatory momentum, product approvals/market uptake, cost discipline and pipeline advances) modestly outweigh the lowlights, supporting a constructive but cautious outlook.View all MX:MRNA earnings summariesMRNA Revenue Breakdown
61.68% U.S.
2.73% Europe
35.60% Rest of World
MRNA Stock 12 Month Forecast
Average Price Target
$1,903.05
▼(-24.15% Downside)